Carpinteri, R., Porcelli, T., Mejia, C., Patelli, I., Bilezikian, J. P., Canalis, E., Angeli, A., Giustina, A., & Mazziotti, G. (2010). Glucocorticoid-induced osteoporosis and parathyroid hormone. Journal of Endocrinological Investigation, 33(7 Suppl), 16-21.
Glucocorticoid-induced osteoporosis and parathyroid hormone. / Carpinteri, R.; Porcelli, T.; Mejia, C. et al.
In:
Journal of Endocrinological Investigation, Vol. 33, No. 7 Suppl, 2010, p. 16-21.
Research output: Contribution to journal › Review article › peer-review
Carpinteri, R, Porcelli, T, Mejia, C, Patelli, I, Bilezikian, JP, Canalis, E, Angeli, A, Giustina, A & Mazziotti, G 2010, 'Glucocorticoid-induced osteoporosis and parathyroid hormone.', Journal of Endocrinological Investigation, vol. 33, no. 7 Suppl, pp. 16-21.
Carpinteri R, Porcelli T, Mejia C, Patelli I, Bilezikian JP, Canalis E et al. Glucocorticoid-induced osteoporosis and parathyroid hormone. Journal of Endocrinological Investigation. 2010;33(7 Suppl):16-21.
Carpinteri, R. ; Porcelli, T. ; Mejia, C. et al. / Glucocorticoid-induced osteoporosis and parathyroid hormone. In: Journal of Endocrinological Investigation. 2010 ; Vol. 33, No. 7 Suppl. pp. 16-21.
@article{85ecfc67351745e58cf353e79cda8321,
title = "Glucocorticoid-induced osteoporosis and parathyroid hormone.",
abstract = "Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Bisphosphonates are considered the first-line treatment option for the majority of glucocorticoid-treated patients at increased risk of fractures. However, the anti-resorptive mechanism of bisphosphonates does not address the major pathophysiological mechanisms of impaired bone formation during chronic glucocorticoid treatment. PTH, when administered intermittently and at low doses, has effects on bone formation opposite to those of glucocorticoids and therefore is conceptually a more attractive approach. Teriparatide (1-34PTH) has been studied in patients with GIO with effects on bone mineral density and on fracture risk which were shown to be superior to those obtained with alendronate.",
author = "R. Carpinteri and T. Porcelli and C. Mejia and I. Patelli and Bilezikian, {J. P.} and E. Canalis and A. Angeli and A. Giustina and G. Mazziotti",
year = "2010",
language = "English",
volume = "33",
pages = "16--21",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Editrice Kurtis s.r.l.",
number = "7 Suppl",
}
TY - JOUR
T1 - Glucocorticoid-induced osteoporosis and parathyroid hormone.
AU - Carpinteri, R.
AU - Porcelli, T.
AU - Mejia, C.
AU - Patelli, I.
AU - Bilezikian, J. P.
AU - Canalis, E.
AU - Angeli, A.
AU - Giustina, A.
AU - Mazziotti, G.
PY - 2010
Y1 - 2010
N2 - Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Bisphosphonates are considered the first-line treatment option for the majority of glucocorticoid-treated patients at increased risk of fractures. However, the anti-resorptive mechanism of bisphosphonates does not address the major pathophysiological mechanisms of impaired bone formation during chronic glucocorticoid treatment. PTH, when administered intermittently and at low doses, has effects on bone formation opposite to those of glucocorticoids and therefore is conceptually a more attractive approach. Teriparatide (1-34PTH) has been studied in patients with GIO with effects on bone mineral density and on fracture risk which were shown to be superior to those obtained with alendronate.
AB - Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Bisphosphonates are considered the first-line treatment option for the majority of glucocorticoid-treated patients at increased risk of fractures. However, the anti-resorptive mechanism of bisphosphonates does not address the major pathophysiological mechanisms of impaired bone formation during chronic glucocorticoid treatment. PTH, when administered intermittently and at low doses, has effects on bone formation opposite to those of glucocorticoids and therefore is conceptually a more attractive approach. Teriparatide (1-34PTH) has been studied in patients with GIO with effects on bone mineral density and on fracture risk which were shown to be superior to those obtained with alendronate.
UR - http://www.scopus.com/inward/record.url?scp=79952108322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952108322&partnerID=8YFLogxK
M3 - Review article
C2 - 20938221
AN - SCOPUS:79952108322
SN - 0391-4097
VL - 33
SP - 16
EP - 21
JO - Journal of Endocrinological Investigation
JF - Journal of Endocrinological Investigation
IS - 7 Suppl
ER -